McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Andrew Williams is quoted in a December 4, 2013 FDA News article entitled, “Idenix Sues to Delay Market Entry of Gilead’s Competing Hep C Candidate.” Following setbacks to its hepatitis C drug program, Idenix Pharmaceuticals is appealing to the courts to keep Gilead’s competing hepatitis C treatment off pharmacy shelves. View the article